Opinions
- Bob MasonCOVID-19 Vaccine Update – AstraZeneca Releases Trial Results
AstraZeneca and the University of Oxford fail to impress the markets with phase 3 trial results. Logistics and production could favor their vaccine, however.
- Bob MasonCOVID-19 Vaccine Update – Pfizer Inc. Submits an EUA
Pfizer Inc. and BioNTech submit a EUA. Moderna Inc. and AstraZeneca need to catch up…
- Bob MasonBrexit – Talks Hit Pause, with Calls for an Extension Beginning to Surface
Brexit talks hit pause as EU negotiators self-isolate. With the transition period ending in just over a month, is an extension around the corner?
- Bob MasonCOVID-19 Vaccine Update – The Numbers are Impressive but the Markets Need More
Pfizer Inc. addresses safety concerns and virus efficacy amongst the elderly. Is it enough for the FDA to approve and for manufacturing to commence?
- Bob MasonBrexit – Politics is a Game and Neither Side Wants to Concede
The proverbial can continues to get kicked down the road. Brexit talks continue and the EU Summit on Thursday may not be the end of it.
- Bob MasonCOVID-19 – Moderna Delivers Even More Impressive Results
Moderna Inc. delivers the world with yet more hope of an end to the global pandemic. More data is going to be needed, however.
- Bob MasonCOVID-19 – Updates on Vaccine Trials are coming. Is Pfizer Still out Ahead?
More clinical trial results are due out from Pharmas in the coming weeks. Safety, duration, and manufacturing data from Pfizer will also be in focus.
- Bob MasonWhite House Down – Trump’s Ultimate Mission?
Anarchy or an orderly handover? There are reasons why the markets should worry…
- Bob MasonBrexit – Another Deadline Gives Negotiators 7-Days to Wrap Up a Deal
It’s the final countdown. EU – UK negotiators have until the 19th November EU Summit to wrap things up.
- Bob MasonCOVID-19 – Pfizer Leads the Race to a COVID-19 Vaccine
Pfizer Inc. and BioNTech SE deliver positive news on Monday. There is a long way to go before a worldwide vaccine, however.
- Bob MasonCOVID-19 – The Race to a Vaccine
The pharmaceutical sector is in a race to deliver an effective COVID-19 vaccine as the 2nd wave hits the West. A number of pharmas lead the way.
- Bob MasonBrexit and U.S Politics – It Could Go Horribly Wrong for Boris and the Brexiteers
Boris Johnson may rue allowing talks to extend beyond October. A Biden victory will put the cat amongst the pigeons…
- Bob MasonCOVID-19 Hits Europe and the U.S Once More. How Will Asian Governments Respond?
The 2nd wave of the COVID-19 pandemic could have a far more severe economic impact. Can Asia avoid the meltdown?
- Bob MasonU.S Presidential Election Jitters Begin to Hit the Markets
There’s a week to go before the U.S Presidential Election. The swing states are back in focus and it’s not a sure thing for Joe Biden…
- Bob MasonBiden Leads Trump ahead of Tomorrow’s Debate. The Polls Give Trump Little Hope…
Trump trails Biden on the eve of the final live televised debate. The latest polls show that Trump needs to more than impress in tomorrow’ debate…
- Bob MasonBrexit – The Mexican Standoff Continues
With both sides unwilling to make the first move, the Mexican Standoff looks set to continue. Will it be Macron or Johnson how blinks first?
- Bob MasonThe U.S Presidential Election – Trump Trails, with Swing States Leaning towards Biden
Trump continues trailed Biden, with polls projecting swing states shifting in Biden’s favor. Trump has less than 3 weeks to turn things around.
- Bob MasonBrexit and the EU Summit – Is the Pound in Store for another Brexit Shock?
With the EU Summit tomorrow, the Pound is on the back foot. French President Macron could deliver a telling blow to the Pound…
- Bob MasonU.S President Trump Says No to a Virtual Debate. Another Big Gamble?
Trump trails Biden and time is running out. Does it make sense to say no to a virtual debate after becoming a super spreader?
- Bob MasonTrump Positive for COVID-19 – Impeccable Timing with 1-Month to Go!
Trump has COVID-19. Will voters sympathize? The chances of postponing the election are slim at best, however… Is this a last-ditch attempt to shift voter sentiment?
